logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Minal Barve

University of California System
H指数:33
被引数:6,991

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

DT2216（一种选择性BCL-xL降解剂）的首次人体I期研究，用于治疗复发/难治性实体恶性肿瘤患者

Journal of Hematology & Oncology
IF40.4
2025-11-120
OAAI
Daruka Mahadevan; Minal Barve; Devalingam Mahalingam; Jay Parekh; Michael Kurman; James Strauss; Larry Tremaine; Robert Hromas; Joshua Sills; John McCulloch; John Harkey; Stacy Suberg; Lisa Zimmerman; Guangrong Zheng; Daohong Zhou
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study

Pirtobrutinib，一种高选择性、非共价（可逆）BTKi在复发/难治性滤泡性淋巴瘤中的应用：BRUIN研究1/2期

Blood Advances
IF7.1
2025-08-250
OAAI
Nirav N. Shah; Pier Luigi Zinzani; Michael Wang; Sunita D. Nasta; Ewa Lech-Maranda; Yoshiaki Ogawa; Bita Fakhri; Bryone Kuss; Kaname Miyashita; Krish Patel; Catherine C. Coombs; Shuo Ma; Manish R. Patel; Minal A. Barve; Benoit Tessoulin; Anastasios Stathis; Daisuke Ennishi; Daigo Hashimoto; Kensuke Kojima; Andrew D. Zelenetz
Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

CS5001的安全性及有效性：一项全球性I期a/b、首次人体试验研究，该研究针对接受新型抗ROR1 ADC治疗的晚期淋巴瘤患者。

BLOOD
IF23.1
2024-11-050
PRE
Song, Yuqin; Zhang, Jian; Zhou, Keshu; Zhang, Liling; Barve, Minal; Lemech, Charlotte; Li, Wenyu; Cherng, Hua-Jay J.; Huang, He; Xie, Linna; Zuniga, Richard; Zhou, Caicun; Shen, Lin; Yang, Shujun; Bishnoi, Sarwan; Zhang, Yan; Wang, Jingru; Zhu, Xiaoli; Li, Eei; Yang, Jason
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
HAEMATOLOGICA
IF7.9
2024-10-032
OAAI
Shah, Nirav N.; Wang, Michael; Roeker, Lindsey E.; Patel, Krish; Woyach, Jennifer A.; Wierda, William G.; Ujjani, Chaitra S.; Eyre, Toby A.; Zinzani, Pier Luigi; Alencar, Alvaro J.; Ghia, Paolo; Lamanna, Nicole; Hoffmann, Marc S.; Patel, Manish R.; Flinn, Ian; Gerson, James N.; Ma, Shuo; Coombs, Catherine C.; Cheah, Chan Y.; Lech-Maranda, Ewa; Fakhri, Bita; Kim, Won Seog; Barve, Minal A.; Cohen, Jonathon B.; Jurczak, Wojciech; Munir, Talha; Thompson, Meghan C.; Tsai, Donald E.; Bao, Katherine; Cangemi, Nicholas A.; Kherani, Jennifer F.; Walgren, Richard A.; Han, Hongmei; Ruppert, Amy S.; Brown, Jennifer R.
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Tgf β 抑制剂SAR439459作为单药治疗和与cemiplimab联合治疗晚期实体瘤患者的安全性，药代动力学，药效学和抗肿瘤活性: 1/1b期研究的结果

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
2024-06-191
OA
Baranda, Joaquina C.; Robbrecht, Debbie; Sullivan, Ryan; Doger, Bernard; Santoro, Armando; Barve, Minal; Grob, Jean-Jacques; Bechter, Oliver; Vieito, Maria; de Miguel, Maria Jose; Schadendorf, Dirk; Johnson, Melissa; Pouzin, Clemence; Cantalloube, Cathy; Wang, Rui; Lee, Jooyun; Chen, Xiaofei; Demers, Brigitte; Amrate, Amele; Abbadessa, Giovanni; Hodi, F. Stephen
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer

Adagrasib联合西妥昔单抗治疗KRASG12C-Mutated转移性结直肠癌的疗效和安全性

CANCER DISCOVERY
IF33.3
2024-04-0811
OAAI
Yaeger, Rona; Uboha, Nataliya V.; Pelster, Meredith S.; Bekaii-Saab, Tanios S.; Barve, Minal; Saltzman, Joel; Sabari, Joshua K.; Peguero, Julio A.; Paulson, Andrew Scott; Janne, Pasi A.; Cruz-Correa, Marcia; Anderes, Kenna; Velastegui, Karen; Yan, Xiaohong; Der-Torossian, Hirak; Klempner, Samuel J.; Kopetz, Scott E.
First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Van Tine, Brian A.; Ahn, Eugene; Redman, Rebecca A.; Barve, Minal A.; Edenfield, William J.; Peguero, Julio; Villaflor, Victoria M.; Rasco, Drew W.; Powell, Steven F.; Mamuye, Admasu T.; Moore, Chris B.; Pelham, Joshua M.; Charoenthongtrakul, Soratree; Spigel, David R.
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors

尼拉帕尼片在晚期实体瘤患者中的相对生物利用度，生物等效性和食物效应研究

CLINICAL THERAPEUTICS
IF3.6
2024-03-010
OAAI
Falchook, Gerald; Patnaik, Amita; Richardson, Debra L.; Harvey, R. Donald; Sharma, Manish R.; Hafez, Navid; Hamilton, Erika; Piha-Paul, Sarina A.; Barve, Minal; Wise-Draper, Trisha; Patel, Manish R.; Dowlati, Afshin; Pascuzzo, Joseph; Tang, Shou-Ching; Faltermeier, Christina; Malinowska, Izabela A.; Shtessel, Luda; Striha, Alina; Potocka, Elizabeth
Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-015
PRE
Spira, Alexander I.; Starodub, Alexander N.; Arbour, Kathryn C.; Sommerhalder, David; Wolpin, Brian M.; Barve, Minal; Garrido-Laguna, Ignacio; Punekar, Salman; Pelster, Meredith; Kar, Sumit; Wong, Jamie; Lin, Tong; Raman, Rakesh; Tao, Lin; Salman, Zeena; Wang, Xiaolin; Gustafson, W. Clay; Hong, David S.
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ERD/HER2L breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

lasofoxifene联合abemaciclib治疗转移性ERD/HER2L乳腺癌和先前治疗疾病进展后ESR1突变的女性的开放标签，II期，多中心研究: ELAINE 2

ANNALS OF ONCOLOGY
IF65.4
2023-12-0114
OA
Damodaran, S.; O'Sullivan, C. C.; Elkhanany, A.; Anderson, I. C.; Barve, M.; Blau, S.; Cherian, M. A.; Peguero, J. A.; Goetz, M. P.; Plourde, P., V; Portman, D. J.; Moore, H. C. F.
Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Hernandez, Genevive; Bilic, Sanela; Guan, Yinghui; So, John; Bhattacharya, Sabya; Wang, Beatrice; Kotturi, Maya; Oyasu, Miho; Desbois, Melanie; Cao, Yuan; Humke, Eric; Ahern, Sean; Sinclair, Angus; Ulahannan, Susanna; Subbiah, Vivek; Pelster, Merideth; Lorusso, Patricia; Falchook, Gerald; Wang, Judy; Barve, Minal; Grewal, Jaspreet; Chow, Warren; Henry, Jason; Cecchini, Michael; Takimoto, Chris; Leabman, Maya

研究方向

暂未获取到该数据
J
John Nemunaitis
H 指数:92论文数:808被引数:3.5万
A
Alexander I. Spira
H 指数:67论文数:943被引数:2.8万
M
Melissa L. Johnson
H 指数:65论文数:838被引数:2.3万
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.6万
A
Amita Patnaik
H 指数:77论文数:744被引数:3.5万
V
Vivek Subbiah
H 指数:78论文数:1,437被引数:3.1万
E
Erika Hamilton
H 指数:58论文数:843被引数:1.6万
M
Manish R. Patel
H 指数:58论文数:790被引数:1.6万
J
Judy Wang
H 指数:22论文数:81被引数:2,099
J
Jason T. Henry
H 指数:16论文数:164被引数:1,082